Lake Street Capital Begins Coverage on ENDRA Life Sciences (NDRA)
Lake Street Capital assumed coverage on shares of ENDRA Life Sciences (NASDAQ:NDRA) in a report issued on Monday morning, The Fly reports. The brokerage issued a buy rating on the stock.
Shares of NASDAQ:NDRA opened at $1.23 on Monday. ENDRA Life Sciences has a 1 year low of $1.00 and a 1 year high of $5.75.
ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.28) earnings per share (EPS) for the quarter.
Institutional investors have recently bought and sold shares of the stock. National Asset Management Inc. purchased a new stake in ENDRA Life Sciences during the fourth quarter valued at $35,000. Creative Planning purchased a new stake in ENDRA Life Sciences during the fourth quarter valued at $53,000. ICM Asset Management Inc. WA increased its position in ENDRA Life Sciences by 412.9% during the fourth quarter. ICM Asset Management Inc. WA now owns 671,226 shares of the company’s stock valued at $1,007,000 after acquiring an additional 540,356 shares during the last quarter. Virtu Financial LLC increased its position in ENDRA Life Sciences by 109.2% during the first quarter. Virtu Financial LLC now owns 28,602 shares of the company’s stock valued at $47,000 after acquiring an additional 14,930 shares during the last quarter. Finally, Geode Capital Management LLC purchased a new stake in ENDRA Life Sciences during the fourth quarter valued at $71,000. Institutional investors own 19.00% of the company’s stock.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
See Also: Special Dividends
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.